Skip to main content

Remote Job Finders (RJF)

JPM26: With Leqembi Launched, Biogen Looks To Expand Alzheimer’s Presence

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with Eli Lilly and its Kisunla offering—is focused on a near-term FDA decision for a subcutaneous induction dose of Leqembi, a presymptomatic readout in 2028 and a clutch of next-generation candidates.

JPM26: Lilly Plots Path to Dominance as Obesity Market Enters a New Era

BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient access improves.

JPM26: AstraZeneca’s Path to $80B by 2030 Paved With ADCs, Cell Therapies, Near-Term Launches

AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs for hypertension, breast cancer and generalized myasthenia gravis, all of which are currently under FDA review.
Scroll to top